EMERGENT BIOSOLUTIONS INC. Deferred Income Tax Liabilities, Net
EMERGENT BIOSOLUTIONS INC. (EBS) had Deferred Income Tax Liabilities, Net of $35.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Liabilities, Net $35.40M.
- 2026-03-31: Deferred Income Tax Liabilities, Net $33.30M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $37.80M.
- 2025-09-30: Deferred Income Tax Liabilities, Net $36.30M.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2026-06-30 | $35.40M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $33.30M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $37.80M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $36.30M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $46.50M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $60.40M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $41.70M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $41.90M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $34.80M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $34.80M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $47.20M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $52.40M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $57.90M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $59.70M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $59.70M 10-K · filed 2024-03-08 | $71.80M 10-K · filed 2023-03-01 |
| 2022-09-30 | $113.90M 10-Q · filed 2023-12-11 | $113.80M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $93.40M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $94.80M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $93.30M 10-K/A · filed 2023-12-11 | $94.90M 10-K · filed 2022-02-25 |
| 2021-09-30 | $53.00M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $53.20M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $53.30M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $53.20M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $64.00M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $63.90M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $63.90M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $63.90M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $61.10M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $65.60M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $66.40M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $67.50M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |